Time to Intubation Is Associated with Outcome in Patients with Community-Acquired Pneumonia

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Hraiech, Sami ^a,e   Alingrin, Julie ^a,e   Dizier, Stéphanie ^a,e   Brunet, Julie ^b   Forel, Jean Marie ^a,e   La Scola, Bernard ^c   Roch, Antoine ^a,e   Papazian, Laurent ^a,e   Pauly, Vanessa ^d,f  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Direction de la Recherche Clinique   (France)

^c AIX MARSEILLE UNIVERSITÉ   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e HÔPITAL NORD   (France)

^f Hopitaux Sud AP HM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; RESPIRATORY TRACT INTUBATION; RISK ASSESSMENT; SURVIVAL PREDICTION; THERAPY DELAY; TIME TO TREATMENT; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; INTUBATION; MALE; MIDDLE AGED; PNEUMONIA; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884376272     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074937     Document Type: Article

References (40)

1. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, et al. (2008) SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 47: 375-384.
2. Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, et al. (2009) Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 48: 377-385.
3. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, et al. (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44Suppl 2: S27-72.
4. Renaud B, Brun-Buisson C, Santin A, Coma E, Noyez C, et al. (2012) Outcomes of early, late, and no admission to the intensive care unit for patients hospitalized with community-acquired pneumonia. Acad Emerg Med 19: 294-303.
5. Yandiola PP, Capelastegui A, Quintana J, Diez R, Gorordo I, et al. (2009) Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 135: 1572-1579.
6. Niederman MS, Luna CM, (2012) Community-acquired pneumonia guidelines: a global perspective. Semin Respir Crit Care Med 33: 298-310.
7. Niederman MS, Chang JR, Stewart J, Asche CV, Lavin B, et al. (2004) Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials. Curr Med Res Opin 20: 969-980.
8. Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, et al. (2002) Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 166: 717-723.
9. Rello J, (2008) Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Crit Care 12Suppl 6: S2.
10. Rello J, Catalan M, Diaz E, Bodi M, Alvarez B, (2002) Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 28: 1030-1035.
11. Torres A, Serra-Batlles J, Ferrer A, Jimenez P, Celis R, et al. (1991) Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 144: 312-318.
12. Niederman MS, (2002) How do we optimize outcomes for patients with severe community-acquired pneumonia? Intensive Care Med 28: 1003-1005.
13. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, et al. (1998) Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 158: 1102-1108.
14. Phua J, Ngerng WJ, Lim TK, (2010) The impact of a delay in intensive care unit admission for community-acquired pneumonia. Eur Respir J 36: 826-833.
15. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A, (2010) Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 137: 552-557.
16. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A, (2008) A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 133: 610-617.
17. Berger P, Papazian L, Drancourt M, La Scola B, Auffray JP, et al. (2006) Ameba-associated microorganisms and diagnosis of nosocomial pneumonia. Emerg Infect Dis 12: 248-255.
18. Coisel Y, Bousbia S, Forel JM, Hraiech S, Lascola B, et al. (2012) Cytomegalovirus and herpes simplex virus effect on the prognosis of mechanically ventilated patients suspected to have ventilator-associated pneumonia. PLoS One 7: e51340.
19. Révision de la IVème conference de consensus en thérapeutique anti-infectieuse de la société de pathologie infectieuse de langue française. Médecine Maladies Infectieuses 30: 566-580.
20. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G,et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 363: 1107-1116.
21. Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, et al. (2009) PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med 37: 456-462.
22. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE, (1981) APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 9: 591-597.
23. Jackson GG, Rana-Sialer JA, Grieble HG, Andersen BR, McCabe WR, (1962) Profiles of pyelonephritis. Arch Intern Med 110: 63-75.
24. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, et al. (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22: 707-710.
25. Le GallJR, Lemeshow S, Saulnier F, (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270: 2957-2963.
26. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, et al. (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58: 377-382.
27. Leroy O, Santre C, Beuscart C, Georges H, Guery B, et al. (1995) A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 21: 24-31.
28. Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P, (1994) Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 105: 1487-1495.
29. Georges H, Leroy O, Vandenbussche C, Guery B, Alfandari S, et al. (1999) Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med 25: 198-206.
30. Leroy O, Georges H, Beuscart C, Guery B, Coffinier C, et al. (1996) Severe community-acquired pneumonia in ICUs: prospective validation of a prognostic score. Intensive Care Med 22: 1307-1314.
31. Rello J, Rodriguez R, Jubert P, Alvarez B, (1996) Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis 23: 723-728.
32. Ruiz M, Ewig S, Torres A, Arancibia F, Marco F, et al. (1999) Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 160: 923-929.
33. Ewig S, de Roux A, Bauer T, Garcia E, Mensa J, et al. (2004) Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 59: 421-427.
34. Ewig S, Torres A, (1999) Severe community-acquired pneumonia: how to assess illness severity. Monaldi Arch Chest Dis 54: 250-254.
35. Demoule A, Girou E, Richard JC, Taille S, Brochard L, (2006) Benefits and risks of success or failure of noninvasive ventilation. Intensive Care Med 32: 1756-1765.
36. Carrillo A, Gonzalez-Diaz G, Ferrer M, Martinez-Quintana ME, Lopez-Martinez A, et al. (2012) Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. Intensive Care Med 38: 458-466.
37. Labelle AJ, Arnold H, Reichley RM, Micek ST, Kollef MH, (2010) A comparison of culture-positive and culture-negative health-care-associated pneumonia. Chest 137: 1130-1137.
38. Chalmers JD, Singanayagam A, Murray MP, Hill AT (2008) Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 121: 1002-1007 e1001.
39. Kollef MH, (2000) Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 31Suppl 4: S131-138.
40. Marrie TJ, Shariatzadeh MR, (2007) Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 86: 103-111.